Histogenics (HSGX) Misses Q2 EPS by 1c
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Histogenics (NASDAQ: HSGX) reported Q2 EPS of ($0.61), $0.01 worse than the analyst estimate of ($0.60).
For earnings history and earnings-related data on Histogenics (HSGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agree Realty (ADC) Tops Q3 FFO by 4c
- Avalonbay Communities (AVB) Reports In-Line Q3 FFO
- Auburn National Bancorp (AUBN) Reports Q3 EPS of $0.54
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!